Literature DB >> 7491530

Indium-111-pentetreotide scanning versus conventional imaging techniques for the localization of gastrinoma.

W J Schirmer, W S Melvin, R M Rush, T M O'Dorisio, R V Pozderac, J O Olsen, E C Ellison.   

Abstract

BACKGROUND: The present study evaluates 111In-pentetreotide scanning as a method for detection of gastrinomas. Operative findings serve as the benchmark for comparison of the efficacy of 111In-pentetreotide versus conventional imaging studies.
METHODS: Twelve patients (seven female and five male; age, 37 to 80 years) with histologic confirmation of gastrinoma underwent thin section dynamic computed tomography (CT) scanning and 111In-pentetreotide scanning. The sensitivity, specificity, positive predictive value, negative predictive value, and accuracy of 111In-pentetreotide and CT scanning are compared on the basis of tumor size and location.
RESULTS: Thirty discrete foci of intrahepatic and extrahepatic tumors were detected at operation. CT scanning detected three of nine pancreaticoduodenal lesions, whereas eight of these nine extrahepatic primary tumors were imaged by 111In-pentetreotide scanning. No false-positive 111In-pentetreotide scans were noted. The sensitivity of CT scanning for detection of metastatic disease was 56% versus 94% for the 111In-pentetreotide scan. Successful CT imaging was highly dependent on tumor size. No tumor smaller than 1 cm was imaged by CT, whereas four of seven lesions greater than 1 cm were imaged by 111In-pentetreotide scintigraphy. The smallest gastrinoma imaged by 111In-pentetreotide scanning was a 4 mm duodenal tumor.
CONCLUSIONS: 111In-pentetreotide scanning was superior to CT scanning for localizing gastrinomas. Further studies are required to determine whether 111In-pentetreotide scans will complement or replace traditional imaging methods.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7491530     DOI: 10.1016/s0039-6060(05)80121-7

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  6 in total

1.  Usefulness of somatostatin receptor scintigraphy in the management of patients with Zollinger-Ellison syndrome. Groupe de Recherche et d'Etude du Syndrome de Zollinger-Ellison (GRESZE).

Authors:  G Cadiot; G Bonnaud; R Lebtahi; L Sarda; P Ruszniewski; D Le Guludec; M Mignon
Journal:  Gut       Date:  1997-07       Impact factor: 23.059

Review 2.  Imaging of neuroendocrine tumors of the pancreas.

Authors:  J L Fidler; C D Johnson
Journal:  Int J Gastrointest Cancer       Date:  2001

Review 3.  Localization of gastrinomas.

Authors:  R A Prinz
Journal:  Int J Pancreatol       Date:  1996-04

4.  Use of radiopharmaceuticals in diagnostic nuclear medicine in the United States: 1960-2010.

Authors:  Vladimir Drozdovitch; Aaron B Brill; Ronald J Callahan; Jeffrey A Clanton; Allegra DePietro; Stanley J Goldsmith; Bennett S Greenspan; Milton D Gross; Marguerite T Hays; Stephen C Moore; James A Ponto; Walton W Shreeve; Dunstana R Melo; Martha S Linet; Steven L Simon
Journal:  Health Phys       Date:  2015-05       Impact factor: 1.316

5.  The Role of 68Ga-DOTATATE Positron Emission Tomography/Computed Tomography in Well-Differentiated Neuroendocrine Tumors: A Case-Based Approach Illustrates Potential Benefits and Challenges.

Authors:  Nitya Raj; Diane Reidy-Lagunes
Journal:  Pancreas       Date:  2018-01       Impact factor: 3.327

6.  Prospective study of somatostatin receptor scintigraphy and its effect on operative outcome in patients with Zollinger-Ellison syndrome.

Authors:  H R Alexander; D L Fraker; J A Norton; D L Bartlett; L Tio; S B Benjamin; J L Doppman; S U Goebel; J Serrano; F Gibril; R T Jensen
Journal:  Ann Surg       Date:  1998-08       Impact factor: 12.969

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.